Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.

Yongkun Sun,Yihebali Chi,Pingzhang Tang,Ming Gao,Qinghai Ji,Zhendong Li,Yuan Zhang,Zhuming Guo,Jun Wang,Xiangjing Chen

Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.

2016

Yongkun Sun
Yihebali Chi
Pingzhang Tang
Ming Gao
Qinghai Ji
Zhendong Li
Yuan Zhang
Zhuming Guo
Jun Wang
Xiangjing Chen

6015Background: Medullary thyroid carcinoma (MTC) is a rare disease with no standard therapies available in China for unresectable, advanced or relapsed MTC patients. Anlotinib is a multi-target RT...

Keywords:

Carcinoma
Medullary cavity
Thyroid
Pathology
General surgery
Medicine
Rare disease
Phases of clinical research
thyroid carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations